During the last session, C4 Therapeutics Inc (NASDAQ:CCCC)’s traded shares were 0.8 million, with the beta value of the company hitting 2.96. At the end of the trading day, the stock’s price was $3.74, reflecting an intraday gain of 0.81% or $0.03. The 52-week high for the CCCC share is $11.88, that puts it down -217.65 from that peak though still a striking 9.63% gain since the share price plummeted to a 52-week low of $3.38. The company’s market capitalization is $264.01M, and the average intraday trading volume over the past 10 days was 1.95 million shares, and the average trade volume was 1.57 million shares over the past three months.
C4 Therapeutics Inc (CCCC) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 1.67. CCCC has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.44.
C4 Therapeutics Inc (NASDAQ:CCCC) trade information
C4 Therapeutics Inc (CCCC) registered a 0.81% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.81% in intraday trading to $3.74, hitting a weekly high. The stock’s 5-day price performance is -7.43%, and it has moved by -2.73% in 30 days. Based on these gigs, the overall price performance for the year is -34.39%. The short interest in C4 Therapeutics Inc (NASDAQ:CCCC) is 8.6 million shares and it means that shorts have 4.24 day(s) to cover.
The consensus price target of analysts on Wall Street is $16, which implies an increase of 76.62% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $20 respectively. As a result, CCCC is trading at a discount of -434.76% off the target high and -220.86% off the low.
C4 Therapeutics Inc (CCCC) estimates and forecasts
Statistics show that C4 Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. C4 Therapeutics Inc (CCCC) shares have gone down -42.28% during the last six months, with a year-to-date growth rate more than the industry average at 43.07% against 16.50. In the rating firms’ projections, revenue will increase 72.57% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 4.33M as predicted by 6 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 3.33M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 3.26M and 3.04M respectively. In this case, analysts expect current quarter sales to grow by 32.88% and then jump by 9.69% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -36.05%. While earnings are projected to return 42.65% in 2025.
CCCC Dividends
C4 Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
C4 Therapeutics Inc (NASDAQ:CCCC)’s Major holders
C4 Therapeutics Inc insiders own 11.42% of total outstanding shares while institutional holders control 91.49%, with the float percentage being 103.29%. LYNX1 CAPITAL MANAGEMENT LP is the largest shareholder of the company, while 158.0 institutions own stock in it. As of 2024-06-30, the company held over 6.88 million shares (or 9.9993% of all shares), a total value of $31.79 million in shares.
The next largest institutional holding, with 4.88 million shares, is of RA CAPITAL MANAGEMENT, L.P.’s that is approximately 7.0891% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $22.54 million.
Also, the Mutual Funds coming in first place with the largest holdings of C4 Therapeutics Inc (CCCC) shares are Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund . Data provided on Sep 30, 2024 indicates that Wasatch Ultra Growth Fund owns about 2.61 shares. This amounts to just over 3.70 percent of the company’s overall shares, with a $9.76 million market value. The same data shows that the other fund manager holds slightly less at 2.14, or about 3.03% of the stock, which is worth about $7.99 million.
